Amneal Pharmaceuticals Inc. [NYSE: AMRX] gained 2.71% on the last trading session, reaching $4.93 price per share at the time. The company report on October 15, 2020 that Amneal to Report Third Quarter 2020 Results on November 6, 2020.
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced that the Company will release its third quarter 2020 financial results on Friday, November 6, 2020, prior to market open. The Company will host a conference call and live webcast with the investment community at 8:30 a.m. Eastern Time on November 6, 2020.
The financial results and live webcast will be accessible through the Investor Relations section of the Company’s website at https://investors.amneal.com.
Amneal Pharmaceuticals Inc. represents 147.39 million in outstanding shares, while the company has a total market value of $1.55 billion with the latest information. AMRX stock price has been found in the range of $4.6361 to $4.96.
If compared to the average trading volume of 1.19M shares, AMRX reached a trading volume of 1902942 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Amneal Pharmaceuticals Inc. [AMRX]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for AMRX shares is $4.61 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on AMRX stock is a recommendation set at 3.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Goldman have made an estimate for Amneal Pharmaceuticals Inc. shares, keeping their opinion on the stock as Sell, with their previous recommendation back on July 27, 2020. The new note on the price target was released on May 12, 2020, representing the official price target for Amneal Pharmaceuticals Inc. stock.
The Average True Range (ATR) for Amneal Pharmaceuticals Inc. is set at 0.29, with the Price to Sales ratio for AMRX stock in the period of the last 12 months amounting to 0.89. The Price to Book ratio for the last quarter was 2.37, with the Price to Cash per share for the same quarter was set at 0.85. Price to Free Cash Flow for AMRX in the course of the last twelve months was 5.46 with Quick ratio for the last quarter at 1.60.
Trading performance analysis for AMRX stock
Amneal Pharmaceuticals Inc. [AMRX] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 13.07. With this latest performance, AMRX shares gained by 12.30% in over the last four-week period, additionally plugging by 38.87% over the last 6 months – not to mention a rise of 78.62% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for AMRX stock in for the last two-week period is set at 58.57, with the RSI for the last a single of trading hit 59.05, and the three-weeks RSI is set at 56.51 for Amneal Pharmaceuticals Inc. [AMRX]. The present Moving Average for the last 50 days of trading for this stock 4.35, while it was recorded at 4.59 for the last single week of trading, and 4.22 for the last 200 days.
Amneal Pharmaceuticals Inc. [AMRX]: A deeper dive into fundamental analysis
Operating Margin for any stock indicates how profitable investing would be, and Amneal Pharmaceuticals Inc. [AMRX] shares currently have an operating margin of +0.09 and a Gross Margin at +29.46. Amneal Pharmaceuticals Inc.’s Net Margin is presently recorded at -22.25.
Return on Total Capital for AMRX is now 0.05, given the latest momentum, and Return on Invested Capital for the company is -11.79. Return on Equity for this stock declined to -98.25, with Return on Assets sitting at -9.03. When it comes to the capital structure of this company, Amneal Pharmaceuticals Inc. [AMRX] has a Total Debt to Total Equity ratio set at 1,194.37. Additionally, AMRX Total Debt to Total Capital is recorded at 92.27, with Total Debt to Total Assets ending up at 75.59. Long-Term Debt to Equity for the company is recorded at 1,178.02, with the Long-Term Debt to Total Capital now at 91.01.
Reflecting on the efficiency of the workforce at the company, Amneal Pharmaceuticals Inc. [AMRX] managed to generate an average of -$65,803 per employee. Receivables Turnover for the company is 2.79 with a Total Asset Turnover recorded at a value of 0.41.Amneal Pharmaceuticals Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.60 and a Current Ratio set at 2.30.
Amneal Pharmaceuticals Inc. [AMRX]: An earnings per share (EPS) analysis
With the latest financial reports released by the company, Amneal Pharmaceuticals Inc. posted 0.04/share EPS, while the average EPS was predicted by analysts to be reported at 0.14/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -71.40%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for AMRX. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Amneal Pharmaceuticals Inc. go to -12.10%.
An analysis of insider ownership at Amneal Pharmaceuticals Inc. [AMRX]
There are presently around $501 million, or 69.70% of AMRX stock, in the hands of institutional investors. The top three institutional holders of AMRX stocks are: FOSUN INTERNATIONAL LTD with ownership of 21,521,301, which is approximately 0% of the company’s market cap and around 1.10% of the total institutional ownership; TPG GROUP HOLDINGS (SBS) ADVISORS, INC., holding 16,213,367 shares of the stock with an approximate value of $79.93 million in AMRX stocks shares; and WELLINGTON MANAGEMENT GROUP LLP, currently with $75.62 million in AMRX stock with ownership of nearly 0.102% of the company’s market capitalization.
Positions in Amneal Pharmaceuticals Inc. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 62 institutional holders increased their position in Amneal Pharmaceuticals Inc. [NYSE:AMRX] by around 7,601,713 shares. Additionally, 69 investors decreased positions by around 6,334,496 shares, while 31 investors held positions by with 87,711,533 shares. The mentioned changes placed institutional holdings at 101,647,742 shares, according to the latest SEC report filing. AMRX stock had 29 new institutional investments in for a total of 3,692,885 shares, while 18 institutional investors sold positions of 1,097,336 shares during the same period.